Maze Therapeutics, Inc. income statement MAZE

It recorded a net loss of $131.1 million. Diluted earnings per share were -$3.05. Over the twelve months ended Jun 30, 2026, revenue was $187.5 million and the net loss was $133.6 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Revenue
188
—
Research and development
122
108
Selling, general and administrative
44
34
Operating income
-146
-143
Pretax income
—
-131
Income tax
—
0
Net income
-134
-131
Basic EPS
-2.52
-3.05
Diluted EPS
-2.52
-3.05
Weighted average shares, basic
53
43
Weighted average shares, diluted
53
43
Other measures
Depreciation and amortization
2
2
EBITDA
-144
-140
Margins
Operating margin
-77.66%
—
Profit margin
-71.25%
—
EBITDA margin
-76.64%
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MAZE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
1842295

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.